Current Report Filing (8-k)
August 14 2018 - 7:36AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
August 14, 2018
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey 07070
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
2.02. Results of Operations and Financial Condition.
On
August 14, 2018, Cancer Genetics, Inc. (the “Registrant”) issued a press release regarding financial results for the
fiscal quarter ended June 30, 2018. A copy of the press release and slide presentation are furnished as Exhibit 99.1 and Exhibit
99.2, respectively, hereto and are incorporated by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, contains forward-looking statements within the meaning of
the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,”
“should,” “plan,” “expect,” “anticipate,” “estimate” and similar words,
and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements
involve known and unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which
may be beyond the Registrant’s control, and which may cause actual results, performance or achievements to be materially
different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements
other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking
statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections
of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management
for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time
to time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2017 and quarter ended March 31, 2018. These risks could cause actual results to differ materially
from those expressed in any forward- looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent
the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected
in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such
expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update
any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future
events or otherwise.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CANCER
GENETICS, INC.
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Date:
August 14, 2018
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2023 to Apr 2024